Masahiro Natsuaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masahiro Natsuaki has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Koichi Node
Department of Cardiovascular Medicine, Saga University, Saga, Japan
6 shared publicationsGoro Yoshioka
Department of Cardiovascular Medicine, Saga University, Saga, Japan
4 shared publicationsKensuke Yokoi
Department of Cardiovascular Medicine, Saga University, Saga, Japan
4 shared publicationsAtsushi Kawaguchi
Education and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga, Japan
3 shared publicationsMitsuhiro Shimomura
Department of Cardiology, Ureshino Medical Hospital, Saga, Japan
3 shared publicationsShinjo Sonoda
Department of Cardiovascular Medicine, Saga University, Saga, Japan
3 shared publications
Latest Publications
- 3 April 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 247, 57-63
Clinical Characteristics and Outcomes Stratified by Time to ST-Segment Elevation Myocardial Infarction Presentation
- 3 April 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 247, 57-63
Clinical Characteristics and Outcomes Stratified by Time to ST-Segment Elevation Myocardial Infarction Presentation
- Open Access
- 25 March 2025
- Published by The Japanese Coronary Association in Journal of Coronary Artery Disease
- Vol. 31 (1) , 5-10
P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention
Antiplatelet therapy following percutaneous coronary intervention (PCI) has evolved along with the development of antiplatelet agents and coronary stents. The use of P2Y12 inhibitor monotherapy is gradually replacing aspirin monotherapy after PCI, as supported by emerging evidence. Aspirin-free P2Y12 inhibitor monotherapy has also been investigated in several prospective studies as a novel antiplatelet therapy for patients undergoing PCI. This brief review highlights the current status of P2Y12 inhibitor monotherapy and offers future perspectives on its use after PCI.
- 25 March 2025
- Published by The Japanese Coronary Association in Journal of Coronary Artery Disease
- Vol. 31 (1) , 5-10
Open AccessP2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention
Antiplatelet therapy following percutaneous coronary intervention (PCI) has evolved along with the development of antiplatelet agents and coronary stents. The use of P2Y12 inhibitor monotherapy is gradually replacing aspirin monotherapy after PCI, as supported by emerging evidence. Aspirin-free P2Y12 inhibitor monotherapy has also been investigated in several prospective studies as a novel antiplatelet therapy for patients undergoing PCI. This brief review highlights the current status of P2Y12 inhibitor monotherapy and offers future perspectives on its use after PCI.
- 3 March 2022
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 37 (2) , 255-263
Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives
Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The recommendation of dual antiplatelet therapy duration is getting shorter due to the decreased risk of stent thrombosis in new-generation DES, the use of a P2Y12 inhibitor as a monotherapy, and the increasing prevalence of high bleeding risk patients. Antithrombotic therapy after PCI has also changed due to the introduction of direct oral anticoagulants. Aspirin-free P2Y12 inhibitor monotherapy is now being evaluated in several prospective studies as a novel strategy of antiplatelet therapy after PCI. This review shows a current status and provides future perspectives for the antiplatelet therapy after PCI.
- 3 March 2022
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 37 (2) , 255-263
Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives
Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The recommendation of dual antiplatelet therapy duration is getting shorter due to the decreased risk of stent thrombosis in new-generation DES, the use of a P2Y12 inhibitor as a monotherapy, and the increasing prevalence of high bleeding risk patients. Antithrombotic therapy after PCI has also changed due to the introduction of direct oral anticoagulants. Aspirin-free P2Y12 inhibitor monotherapy is now being evaluated in several prospective studies as a novel strategy of antiplatelet therapy after PCI. This review shows a current status and provides future perspectives for the antiplatelet therapy after PCI.
- 1 January 2022
- Published by Elsevier in International Journal of Cardiology
- Vol. 346, 1-7
Simple risk-score model for in-hospital major bleeding based on multiple blood variables in patients with acute myocardial infarction
- 1 January 2022
- Published by Elsevier in International Journal of Cardiology
- Vol. 346, 1-7
Simple risk-score model for in-hospital major bleeding based on multiple blood variables in patients with acute myocardial infarction
- Open Access
- 25 May 2021
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 85 (6) , 794-796
Is It Time to Shift the Monotherapy After Percutaneous Coronary Intervention From Aspirin to P2Y12 Inhibitors? ― New Normal in the New-Generation Era ―
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 25 May 2021
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 85 (6) , 794-796
Open AccessIs It Time to Shift the Monotherapy After Percutaneous Coronary Intervention From Aspirin to P2Y12 Inhibitors? ― New Normal in the New-Generation Era ―
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies